SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06208033 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

EGFR Positive Non-small Cell Lung Cancer

Interventions

DRUG: SMET12
DRUG: SMET12
DRUG: SMET12

Sponsor

Fujian Cancer Hospital